CeriBell (NASDAQ:CBLL) CTO Sells $118,900.71 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $24.33, for a total value of $118,900.71. Following the completion of the transaction, the chief technology officer owned 203,118 shares in the company, valued at $4,941,860.94. The trade was a 2.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Raymond Woo also recently made the following trade(s):

• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58.

CeriBell Price Performance

CeriBell stock opened at $23.63 on Friday. The company has a fifty day simple moving average of $21.11 and a 200-day simple moving average of $19.64. The firm has a market capitalization of $906.92 million, a price-to-earnings ratio of -13.43 and a beta of 0.95. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The business had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. On average, equities analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after buying an additional 374,179 shares during the last quarter. Rhumbline Advisers raised its position in shares of CeriBell by 109.9% during the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after buying an additional 17,177 shares during the period. New York State Common Retirement Fund lifted its holdings in CeriBell by 148.6% in the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after acquiring an additional 5,200 shares during the last quarter. Quantbot Technologies LP increased its stake in CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after acquiring an additional 6,401 shares during the last quarter. Finally, Invesco Ltd. acquired a new stake in CeriBell during the second quarter worth $197,000.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CBLL shares. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 28th. Raymond James Financial reiterated a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. Canaccord Genuity Group boosted their price objective on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. BTIG Research reissued a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Friday. Finally, Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.